Predict your next investment

Debt & Specialty Finance
FINANCIAL | Investment Firms & Funds
atel.com/ventures

See what CB Insights has to offer

Investments

98

Portfolio Exits

19

Funds

9

About ATEL Ventures

ATEL Ventures is a provider of senior secured financing to emerging growth companies. AVI's role is to partner with venture capital firms to support pre-IPO and growth companies from the ground up.

ATEL Ventures Headquarter Location

600 Montgomery Street 9th Floor

San Francisco, California, 94111,

United States

800-543-2835

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing ATEL Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find ATEL Ventures in 3 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

I

Industrial SynBio

382 items

Synthetic biology focused on replacing industrial and commercial materials.

ATEL Ventures Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ATEL Ventures Rank

Latest ATEL Ventures News

iPierian Raises $30M; Funds True North Therapeutics

Sep 4, 2013

By FinSMEs iPierian, Inc. , a South San Francisco, California-based biotechnology company developing novel therapies for neurodegenerative disease, raised $30m in financing. The round was co-led by SR One, Kleiner Perkins Caufield & Byers and MPM Capital with participation from existing investors (which are Google Ventures, Mitsubishi UFJ Capital, Atel Ventures, Highland Capital Partners, and FinTech Global Capital). The company intends to use the funds: – to accelerate the clinical development program for IPN007, a monoclonal antibody targeting the Tau protein for the treatment of Alzheimer’s disease and other tauopathies (e.g. progressive supranuclear palsy, frontotemporal dementia) planning to file an Investigational New Drug (IND) application with the U.S. FDA in 2014; – to provide a Series A round to launch a South San Francisco, California-based  spin-out company, True North Therapeutics , to advance its lead drug candidate TNT009, a monoclonal antibody that selectively inhibits a target of the Classical Complement pathway, into clinical trials. Nancy Stagliano will serve as Chief Executive Officer of both iPierian and True North Therapeutics. As part of the financing, Rajeev Dadoo from SR One will join the Board of Directors of both companies. FinSMEs 04/09/2013

ATEL Ventures Investments

98 Investments

ATEL Ventures has made 98 investments. Their latest investment was in Emulate as part of their Series B - II on October 10, 2016.

CBI Logo

ATEL Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/20/2016

Series B - II

Emulate

$17M

No

+ND Capital, ALS Finding A Cure, Cedars-Sinai Medical Center, Hansjörg Wyss, LabCorp, and OS Fund

5

3/28/2016

Series B

Emulate

$28.75M

Yes

+ND Capital, ALS Finding A Cure, Cedars-Sinai Medical Center, Hansjörg Wyss, LabCorp, and OS Fund

7

5/1/2014

Debt

Tegile Systems

$0.5M

Yes

5/1/2014

Debt - II

Subscribe to see more

$99M

Subscribe to see more

10

4/7/2014

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/20/2016

3/28/2016

5/1/2014

5/1/2014

4/7/2014

Round

Series B - II

Series B

Debt

Debt - II

Series C

Company

Emulate

Emulate

Tegile Systems

Subscribe to see more

Subscribe to see more

Amount

$17M

$28.75M

$0.5M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

+ND Capital, ALS Finding A Cure, Cedars-Sinai Medical Center, Hansjörg Wyss, LabCorp, and OS Fund

+ND Capital, ALS Finding A Cure, Cedars-Sinai Medical Center, Hansjörg Wyss, LabCorp, and OS Fund

Sources

5

7

10

10

ATEL Ventures Portfolio Exits

19 Portfolio Exits

ATEL Ventures has 19 portfolio exits. Their latest portfolio exit was DigitalOcean on March 24, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/24/2021

IPO

$991

2

1/14/2021

Acquired

5

10/23/2019

Acquired

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

3/24/2021

1/14/2021

10/23/2019

00/00/0000

00/00/0000

Exit

IPO

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

2

5

1

10

10

ATEL Ventures Fund History

9 Fund Histories

ATEL Ventures has 9 funds, including ATEL Institutional Venture Debt Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

5/2/2018

ATEL Institutional Venture Debt Fund

$30.2M

3

6/10/2016

ATEL Portsmouth Growth Capital Fund

Subscribe to see more

$99M

10

1/29/2007

Atel Growth Capital Fund II

Subscribe to see more

$99M

10

Atel Growth Capital Fund VI

Subscribe to see more

$99M

10

Atel Growth Capital Fund IV

Subscribe to see more

$99M

10

Closing Date

5/2/2018

6/10/2016

1/29/2007

Fund

ATEL Institutional Venture Debt Fund

ATEL Portsmouth Growth Capital Fund

Atel Growth Capital Fund II

Atel Growth Capital Fund VI

Atel Growth Capital Fund IV

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$30.2M

$99M

$99M

$99M

$99M

Sources

3

10

10

10

10

ATEL Ventures Team

12 Team Members

ATEL Ventures has 12 team members, including current Chief Executive Officer, Dean L. Cash.

Name

Work History

Title

Status

Dean L. Cash

Chief Executive Officer

Current

Steven Rea

Imperial Bank, and LINC

President, Managing Director

Current

Paritosh K. Choksi

Chief Operating Officer

Current

Jonas Kriks

Chief Information Officer

Current

Craig Ault

Executive Vice President

Current

Name

Dean L. Cash

Steven Rea

Paritosh K. Choksi

Jonas Kriks

Craig Ault

Work History

Imperial Bank, and LINC

Title

Chief Executive Officer

President, Managing Director

Chief Operating Officer

Chief Information Officer

Executive Vice President

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.